Trials / Completed
CompletedNCT02526160
Study of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Study With Open-Label Extension to Assess the Efficacy and Safety of KRN23 in Adults With X-linked Hypophosphatemia (XLH)
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 134 (actual)
- Sponsor
- Kyowa Kirin, Inc. · Industry
- Sex
- All
- Age
- 18 Years – 65 Years
- Healthy volunteers
- Not accepted
Summary
The primary efficacy objective of this study is to establish the effect of burosumab treatment compared with placebo on increasing serum phosphorus levels in adults with XLH.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | burosumab | solution for SC injection |
| OTHER | Placebo | saline solution for SC injection |
Timeline
- Start date
- 2015-10-22
- Primary completion
- 2016-12-22
- Completion
- 2018-12-06
- First posted
- 2015-08-18
- Last updated
- 2024-06-18
- Results posted
- 2021-02-05
Locations
25 sites across 7 countries: United States, France, Ireland, Italy, Japan, South Korea, United Kingdom
Source: ClinicalTrials.gov record NCT02526160. Inclusion in this directory is not an endorsement.